On October 2, 2019 Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that data with the Company’s lead product candidate, RP1, will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting in Washington, D.C. from November 6-10, 2019 (Press release, Replimune, OCT 2, 2019, View Source [SID1234540012]). The poster which will be presented on November 8, 2019 highlights results from the Phase 1 portion of the Phase 1/2 clinical trial of RP1 as a single agent and in combination with Opdivo (nivolumab) in patients with solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of Replimune’s poster presentation:
Abstract Title: Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors
Poster #: P433
Date: Friday, November 8, 2019, 7:00 a.m. ET – 8:00 p.m. ET
Location: Gaylord National Hotel & Convention Center